Anticardiolipin antibody in vascular parkinsonism

Zhigao Huang, Michael Jacewicz, Ronald Pfeiffer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini-Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA- groups. Since the presence of ACLA in individuals with stroke is usually treated by full-scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive.

Original languageEnglish (US)
Pages (from-to)992-997
Number of pages6
JournalMovement Disorders
Volume17
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Anticardiolipin Antibodies
Parkinsonian Disorders
Blood Vessels
Stroke
Levodopa
Gait
Movement Disorders
Tremor
Warfarin
Neuroimaging
Coronary Artery Disease
Immunoglobulin G
Hypertension

Keywords

  • Anticardiolipin antibody
  • Gait disorder
  • Vascular parkinsonism

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Anticardiolipin antibody in vascular parkinsonism. / Huang, Zhigao; Jacewicz, Michael; Pfeiffer, Ronald.

In: Movement Disorders, Vol. 17, No. 5, 2002, p. 992-997.

Research output: Contribution to journalArticle

Huang, Zhigao ; Jacewicz, Michael ; Pfeiffer, Ronald. / Anticardiolipin antibody in vascular parkinsonism. In: Movement Disorders. 2002 ; Vol. 17, No. 5. pp. 992-997.
@article{57ad801a54e44d38b72ddfe93e1f0d68,
title = "Anticardiolipin antibody in vascular parkinsonism",
abstract = "Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini-Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82{\%} of the patients, and levodopa responsiveness was present in 18{\%} of those treated. In 9 of the 22 (40.9{\%}), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA- groups. Since the presence of ACLA in individuals with stroke is usually treated by full-scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive.",
keywords = "Anticardiolipin antibody, Gait disorder, Vascular parkinsonism",
author = "Zhigao Huang and Michael Jacewicz and Ronald Pfeiffer",
year = "2002",
doi = "10.1002/mds.10219",
language = "English (US)",
volume = "17",
pages = "992--997",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Anticardiolipin antibody in vascular parkinsonism

AU - Huang, Zhigao

AU - Jacewicz, Michael

AU - Pfeiffer, Ronald

PY - 2002

Y1 - 2002

N2 - Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini-Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA- groups. Since the presence of ACLA in individuals with stroke is usually treated by full-scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive.

AB - Vascular parkinsonism (VP) is characterized by predominantly lower body involvement with gait impairment and postural instability, often without tremor, and by relative levodopa unresponsiveness. Neuroimaging studies demonstrate multiple infarcts or ischemic changes in periventricular white matter. Anticardiolipin antibodies (ACLA) are associated with hypercoagulable states and increased stroke risk. Review of our Movement Disorders Clinic records identified 44 individuals with a diagnosis of VP. ACLA have been obtained in 22 of these patients (mean age, 78.3 years; mean Mini-Mental Status Exam score, 25.8). Gait disturbance was the initial clinical feature in 82% of the patients, and levodopa responsiveness was present in 18% of those treated. In 9 of the 22 (40.9%), ACLA immunoglobulin G was positive. No significant differences in clinical features or risk factors (hypertension, diabetes, coronary artery disease, and clinical stroke) were evident between ACLA+ and ACLA- groups. Since the presence of ACLA in individuals with stroke is usually treated by full-scale anticoagulation with warfarin, our findings raise the question whether such treatment should also be used in persons with VP who are ACLA positive.

KW - Anticardiolipin antibody

KW - Gait disorder

KW - Vascular parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=0036765121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036765121&partnerID=8YFLogxK

U2 - 10.1002/mds.10219

DO - 10.1002/mds.10219

M3 - Article

VL - 17

SP - 992

EP - 997

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 5

ER -